Use of antiviral treatment and prophylaxis is unlikely to have a major impact on the prevalence of herpes simplex virus type 2

Sexually Transmitted Infections

Volumn 75, Issue 1, 1999, Pages 49-54

  White, P J ^a   Garnett, G P ^b  

^a UNIVERSITY OF STIRLING   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Antiviral therapy; Herpes simplex virus type 2; Mathematical model

Indexed keywords

ACICLOVIR; ANTIVIRUS AGENT; DNA;

ARTICLE; GENITAL HERPES; HERPES SIMPLEX VIRUS 2; HUMAN; INFECTION PREVENTION; MATHEMATICAL MODEL; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; VIRUS TRANSMISSION;

EID: 0033048844     PISSN: 13684973     EISSN: None     Source Type: Journal    
DOI: 10.1136/sti.75.1.49     Document Type: Article

References (41)

1. Wald A, Corey L. The clinical features and diagnostic evaluation of genital herpes. In: Stanberry LR, ed. Genital and neonatal herpes. New York: John Wiley, 1996:109-37.
2. Wald A, Zeh J, Barnum G, et al. Suppression of subclinical shedding of herpes simplex virus type 2 with acyclovir. Ann Intern Med 1996;124:8-15.
3. Harknett P. Herpes simplex. London: Thorsons, 1994.
4. Baker DA. Herpes simplex virus infections. Curr Opin Obstet Gynecol 1992;4:676-81.
5. Mindel A. Antiviral chemotherapy for genital herpes. Rev Med Virol 1991;1:111-18.
6. Mertz GI, Critchlow CW, Benedetti J, et al. Double-blind placebo-controlled trial of oral acyclovir in 1st-episode genital herpes-simplex virus-infection. JAMA 1984;252:1147-51.
7. Corey L, Benedetti J, Critchlow C, et al. Treatment of primary 1st episode genital herpes simplex virus infections with acyclovir - results of topical, intravenous and oral therapy. J Antimicrob Chemother 1983;12:79-88.
8. Bryson YJ, Dillon M, Lovett M, et al. Treatment of 1st episodes of genital herpes simplex virus infection with oral acyclovir - a randomized double-blind controlled trial in normal subjects. N Engl J Med 1983;308:916-21.
9. Spruance SL, Tyring SK, Degregorio B, et al. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis Arch Intern Med 1996;156:1729-35.
10. Sacks SL, Aoki FY, Diazmitoma F, et al. Patient-initiated, twice-daily oral famciclovir for early recurrent genital herpes - a randomized, double-blind multicenter trial JAMA 1996;276:44-9.
11. Barton SE. All patients with recurrent genital herpes should be offered suppressive therapy with acyclovir. Rev Med Virol 1996;6:65-6.
12. Patel R. All patients with recurrent genital herpes should not be offered suppressive therapy with acyclovir. Rev Med Virol 1996;6:67-9.
13. Handsfield HH. Acyclovir should not be approved for marketing without prescription. Sex Transm Dis 1996;23:171-3.
14. Wald AD, Koutsky L, Ashley RL, et al. Genital herpes in a primary care clinic: demographic and sexual correlates of herpes simplex type 2 infections. Sex Transm Dis 1997;24:149-55.
15. Wald A, Corey L, Cone R, et al. Frequent genital herpes simplex virus 2 shedding in immunocompetent women: effect of acyclovir treatment. J Clin Invest 1997;99:1029-97.
16. Wald A. Beyond efficacy: new issues for HSV antiviral therapy. Genitourin Med 1997;73:83-4.
17. Fife KH. Over-the-counter acyclovir: an idea whose time has come. Sex Transm Dis 1996;23:174-6.
18. Guinan ME. Oral acyclovir, palliative therapy for genital herpes: will it change the epidemiology? Sex Transm Dis 1985;12:55-6.
19. Anderson RM. The transmission dynamics of sexually transmitted diseases: the behavioral component. In: Wasserheit JN, et al, eds. Research issues in human behavior and sexually transmitted diseases in the AIDS era. Washington, DC: American Society of Microbiology, 1991.
20. Brunham RC, Plummer FA. A general model of sexually transmitted disease epidemiology and its implications for control. Med Clin N Am 1990;74:1339-52.
21. Johnson AM, Wadsworth J, Wellings K, et al. Sexual attitudes and lifestyles. Oxford: Blackwell Scientific Publishers, 1994.
22. Christenson B, Bottiger M, Svensson A, et al. A 15-year surveillence study of antibodies to herpes simplex virus types 1 and 2 in a cohort of young girls. J Infect 1992;25:147-54.
23. Lycke E. The pathogenesis of the genital herpes simplex virus infection. Scand J Infect Suppl 1991;78:7-14.
24. Fleming DT, McQuillan GM, Johnson RE, et al. Herpes simplex virus type 2 in the United States, 1976 to 1994. N Engl J Med 1997;337:1105-11.
25. Stanberry LR, Jorgensen DM, Nahmias AJ. Herpes simplex viruses 1 and 2. In: Evans AS, ed. Viral infections of humans: epidemiology and control. New York: Plenum Medical, 1997:419-54.
26. Hethcote HW, Yorke JA. Gonorrhea transmission dynamics and control. Lecture Notes in Biomathematics. Vol 56. Berlin: Springer-Verlag, 1984.
27. Williams JR, Nokes DJ, Medley GF, et al. The transmission dynamics of hepatitis B in the UK: a mathematical model for evaluating costs and effectiveness of immunization programmes. Epidemiol Infect 1996;116:71-89.
28. Koopman JS, Longini Jr IM, Jacquez JA, et al. Assessing risk factors for transmission of infection. Am J Epidemiol 1991; 133:1199-209.
29. Stanberry LR. The pathogenesis of herpes simplex virus infections. In: Stanberry LR, ed. Genital and neonatal herpes. New York: John Wiley, 1996:31-47.
30. Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983;250:3205-9.
31. Hooper RR, Reynolds GH, Jones, et al. Cohort study of venereal disease. I: The risk of gonorrhoea transmission from infected women to men. Am J Epidemiol 1978;108: 136-44.
32. Mertz GJ, Benedetti J, Ashley R, et al. Risk factors for the sexual transmission of genital herpes. Ann Intern Med 1992;116:197-202.
33. Koelle DM, Benedetti J, Langenberg A, et al. Asymptomatic reactivation of herpes simplex virus in women after the first episode of genital herpes. Ann Intern Med 1992;116:433-7.
34. Nahmias AJ, Lee FK, Keyserling H.L. The epidemiology of genital herpes. In: Stanberry LR, ed. Genital and neonatal herpes. New York: John Wiley, 1996:93-107.
35. Thomas JC, Tucker MJ. The development and use of the concept of a sexually transmitted disease core. J Infect Dis Suppl 1996;174(Suppl 2):S134-43.
36. Garnett GP, Anderson RM. Sexually transmitted infections: insights from mathematical models. J Infect Dis 1996; 174(Suppl 2):S150-61.
37. Strauss SE, Croen KD, Sawyer MH, et al. Acyclovir suppression of frequently recurring genital herpes. JAMA 1988;260:2227-30.
38. Mindel A. Is it meaningful to treat patients with recurrent herpetic infections? Scand J Infect Suppl 1991;78:27-32.
39. Mandell GL, Mildvan D, Stevens DL, et al. Atlas of infectious diseases. Philadelphia: Current Medicine, 1996.
40. Upchurch DM, Brady WE, Reichart CA, et al. Behavioral contributions to acquisition of gonorrhea in patients in patients attending an inner city sexually transmitted disease clinic. J Infect Dis 1990;161:938-41.
41. Wasserheit JN, Aral SO. The dynamic topology of sexually-transmitted disease epidemics - implications for prevention strategies. J Infect Dis 1990;174(Suppl 2):S201-13.